Printer Friendly

CRUCELL LICENSES PER.C6 TECHNOLOGY TO GLAXOSMITHKLINE.

Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics have announced that Crucell has signed a PER.C6 research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6 technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products.

Under the terms of the agreement, Crucell and DSM Biologics will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6[R] technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6[R] technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL).

For more information, visit http://www.crucell.com.

About DSM Biologics

DSM Biologics, a business unit of the DSM Pharmaceutical Products business group, is one of the world's leading contract manufacturers of biopharmaceutical products, the latest generation of drugs, mainly on the basis of native molecules and produced with the help of cell cultures. The company is renowned for its experience in the use of a broad range of cell culture systems (microbial and mammalian) and its expertise in the field of purification techniques. Established in 1986, DSM Biologics currently employs about 450 people, who are based at the company's two sites, one in Groningen, the Netherlands (ca. 1,000 liters fermentor capacity and 6,000 m2 ) and one in Montreal, Quebec, Canada (ca. 6,500 liters fermentor capacity and presently 10,000 m2). DSM Biologics is a joint venture of DSM and Societe generale de financement du Quebec (SGF), an industrial and financial holding company, which carries out economic development projects, especially in the industrial sector, in cooperation with partners and in accordance with accepted requirements for profitability that comply with the economic development policy of the Government of Quebec.

For more information, visit http://www.dsmbiologics.com.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:4EUNE
Date:Oct 1, 2004
Words:425
Previous Article:GENEPHARM BEGINS REGISTRATION OF FIVE ANTI-CANCER DRUGS.
Next Article:SURFAXIN GETS ORPHAN DRUG DESIGNATION FROM EMEA.


Related Articles
Tea Room's $30m price tag.
AERAS/CRUCELL TO DEVELOP TB VACCINE.
$10M Chelsea sale.
Eastern branches out for lumber yard sale.
CRUCELL/MERIAL SIGN LICENSE PACT FOR PER.C6 TECHNOLOGY.
CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
Ron Cohen of Besen Brokers sale of two loft buildings in 'Ladies Mile'.
CRUCELL/US NAVY SIGN PACT TO TEST ADVAC-BASED VACCINE.
CRUCELL APPOINTS AGENTS TO BOOST ASIAN MARKET POTENTIAL.
CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |